{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:23:48Z","timestamp":1788593028847,"version":"build-2803163510"},"reference-count":183,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1A5A2026045"],"award-info":[{"award-number":["NRF-2019R1A5A2026045"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00262332"],"award-info":[{"award-number":["RS-2023-00262332"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Glucose metabolism is essential for the maintenance and function of the central nervous system. Although the brain constitutes only 2% of the body weight, it consumes approximately 20% of the body\u2019s total energy, predominantly derived from glucose. This high energy demand of the brain underscores its reliance on glucose to fuel various functions, including neuronal activity, synaptic transmission, and the maintenance of ion gradients necessary for nerve impulse transmission. Increasing evidence shows that many neurodegenerative diseases, including Parkinson\u2019s disease (PD), are associated with abnormalities in glucose metabolism. PD is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, accompanied by the accumulation of \u03b1-synuclein protein aggregates. These pathological features are exacerbated by mitochondrial dysfunction, oxidative stress, and neuroinflammation, all of which are influenced by glucose metabolism disruptions. Emerging evidence suggests that targeting glucose metabolism could offer therapeutic benefits for PD. Several antidiabetic drugs have shown promise in animal models and clinical trials for mitigating the symptoms and progression of PD. This review explores the current understanding of the association between PD and glucose metabolism, emphasizing the potential of antidiabetic medications as a novel therapeutic approach. By improving glucose uptake and utilization, enhancing mitochondrial function, and reducing neuroinflammation, these drugs could address key pathophysiological mechanisms in PD, offering hope for more effective management of this debilitating disease.<\/jats:p>","DOI":"10.3390\/cells13221876","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:23:16Z","timestamp":1731478996000},"page":"1876","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"13","author":[{"given":"Ahmed","family":"Tanvir","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Ajou University School of Medicine, Suwon 16499, Republic of Korea"},{"name":"Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 16499, Republic of Korea"},{"name":"Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junghyun","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ajou University School of Medicine, Suwon 16499, Republic of Korea"},{"name":"Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 16499, Republic of Korea"},{"name":"Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-4743","authenticated-orcid":false,"given":"Sang Myun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ajou University School of Medicine, Suwon 16499, Republic of Korea"},{"name":"Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon 16499, Republic of Korea"},{"name":"Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon 16499, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","article-title":"Sugar for the brain: The role of glucose in physiological and pathological brain function","volume":"36","author":"Mergenthaler","year":"2013","journal-title":"Trends Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zhang, S., Lachance, B.B., Mattson, M.P., and Jia, X. (2021). Glucose metabolic crosstalk and regulation in brain function and diseases. Prog. Neurobiol., 204.","DOI":"10.1016\/j.pneurobio.2021.102089"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Blazquez, E., Hurtado-Carneiro, V., LeBaut-Ayuso, Y., Velazquez, E., Garcia-Garcia, L., Gomez-Oliver, F., Ruiz-Albusac, J.M., Avila, J., and Pozo, M.A. (2022). Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.873301"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson\u2019s disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/mds.27193","article-title":"Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature","volume":"32","author":"Schneider","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Skrahin, A., Horowitz, M., Istaiti, M., Skrahina, V., Lukas, J., Yahalom, G., Cohen, M.E., Revel-Vilk, S., Goker-Alpan, O., and Becker-Cohen, M. (2024). GBA1-Associated Parkinson\u2019s Disease Is a Distinct Entity. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137102"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.14336\/AD.2021.0422","article-title":"Potential Crosstalk Between Parkinson\u2019s Disease and Energy Metabolism","volume":"12","author":"Liu","year":"2021","journal-title":"Aging Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"110672","DOI":"10.1016\/j.brainresbull.2023.110672","article-title":"Glucose metabolism impairment in Parkinson\u2019s disease","volume":"199","author":"Dai","year":"2023","journal-title":"Brain Res. Bull."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1016\/S0021-9258(18)38267-X","article-title":"Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization","volume":"265","author":"Pardridge","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/1044-7431(91)90066-W","article-title":"Expression of two glucose transporters, GLUT1 and GLUT3, in cultured cerebellar neurons: Evidence for neuron-specific expression of GLUT3","volume":"2","author":"Maher","year":"1991","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1152\/ajpendo.90388.2008","article-title":"The facilitative glucose transporter GLUT3: 20 years of distinction","volume":"295","author":"Simpson","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/glia.440140107","article-title":"The human blood-brain barrier glucose transporter (GLUT1) is a glucose transporter of gray matter astrocytes","volume":"14","author":"Morgello","year":"1995","journal-title":"Glia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1471-4159.1994.62010240.x","article-title":"Developmental expression of GLUT1 and GLUT3 glucose transporters in rat brain","volume":"62","author":"Vannucci","year":"1994","journal-title":"J. Neurochem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00424-020-02441-x","article-title":"Glucose transporters in brain in health and disease","volume":"472","author":"Koepsell","year":"2020","journal-title":"Pflug. Arch."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1523\/JNEUROSCI.14-08-05068.1994","article-title":"Extracellular glucose concentration in mammalian brain: Continuous monitoring of changes during increased neuronal activity and upon limitation in oxygen supply in normo-, hypo-, and hyperglycemic animals","volume":"14","author":"Silver","year":"1994","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2337\/db18-0722","article-title":"Glycemic variability and brain glucose levels in type 1 diabetes","volume":"68","author":"Hwang","year":"2019","journal-title":"Diabetes"},{"key":"ref_17","first-page":"1986","article-title":"Blood-Brain Barrier Transport and Brain Metabolism of Glucose during Acute Hyperglycemia in Humans1","volume":"86","author":"Hasselbalch","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kyrtata, N., Emsley, H.C.A., Sparasci, O., Parkes, L.M., and Dickie, B.R. (2021). A Systematic Review of Glucose Transport Alterations in Alzheimer\u2019s Disease. Front. Neurosci., 15.","DOI":"10.3389\/fnins.2021.626636"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00429-019-01846-4","article-title":"Regional elevations in microglial activation and cerebral glucose utilization in frontal white matter tracts of rhesus monkeys following prolonged cocaine self-administration","volume":"224","author":"Smith","year":"2019","journal-title":"Brain Struct. Funct."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/emm.2016.4","article-title":"Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism","volume":"48","author":"Roh","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.2337\/diabetes.50.7.1618","article-title":"The Effect of Acute Hypoglycemia on Brain Function and Activation: A Functional Magnetic Resonance Imaging Study","volume":"50","author":"Rosenthal","year":"2001","journal-title":"Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ibneur.2022.12.006","article-title":"Molecular mechanisms underlying hyperglycemia associated cognitive decline","volume":"14","author":"Gupta","year":"2023","journal-title":"IBRO Neurosci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/jcbfm.2014.206","article-title":"Lactate transport and signaling in the brain: Potential therapeutic targets and roles in body-brain interaction","volume":"35","author":"Bergersen","year":"2015","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-4159.2005.03168.x","article-title":"Monocarboxylate transporters in the central nervous system: Distribution, regulation and function","volume":"94","author":"Pierre","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/EBC20220075","article-title":"Cross-talk between energy and redox metabolism in astrocyte-neuron functional cooperation","volume":"67","author":"Almeida","year":"2023","journal-title":"Essays Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/ncb1881","article-title":"The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC\/C-Cdh1","volume":"11","author":"Almeida","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/jcbfm.2011.149","article-title":"Sweet sixteen for ANLS","volume":"32","author":"Pellerin","year":"2012","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/01.WCB.0000091761.61714.25","article-title":"Lactate is a preferential oxidative energy substrate over glucose for neurons in culture","volume":"23","author":"Voisin","year":"2003","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1471-4159.1997.69010084.x","article-title":"Expression of the Na+-D-glucose cotransporter SGLT1 in neurons","volume":"69","author":"Poppe","year":"1997","journal-title":"J. Neurochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2147\/DMSO.S258593","article-title":"Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice","volume":"13","author":"Nguyen","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101234","DOI":"10.1016\/j.molmet.2021.101234","article-title":"The brain as an insulin-sensitive metabolic organ","volume":"52","author":"Milstein","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Jorda, A., Aldasoro, M., Campo-Palacio, I., Vila, J.M., Aldasoro, C., Campos-Campos, J., Colmena, C., Singh, S.K., Obrador, E., and Valles, S.L. (2022). Facilitation of Insulin Effects by Ranolazine in Astrocytes in Primary Culture. Int. J. Mol. Sci., 23.","DOI":"10.20944\/preprints202206.0085.v1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1463-1326.2011.01454.x","article-title":"Physiologic action of glucagon on liver glucose metabolism","volume":"13","author":"Ramnanan","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","first-page":"109","article-title":"Glucocorticoids, stress, and fertility","volume":"35","author":"Whirledge","year":"2010","journal-title":"Minerva Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1152\/physrev.00030.2013","article-title":"Thyroid hormone regulation of metabolism","volume":"94","author":"Mullur","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm.2017.95","article-title":"AMPK: Guardian of metabolism and mitochondrial homeostasis","volume":"19","author":"Herzig","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1101\/gad.1529107","article-title":"The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis","volume":"21","author":"Lum","year":"2007","journal-title":"Genes. Dev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cmet.2011.08.016","article-title":"Brain energy metabolism: Focus on astrocyte-neuron metabolic cooperation","volume":"14","author":"Allaman","year":"2011","journal-title":"Cell Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coisb.2017.11.005","article-title":"New concepts in feedback regulation of glucose metabolism","volume":"8","author":"Locasale","year":"2018","journal-title":"Curr. Opin. Syst. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1471-4159.2009.05916.x","article-title":"AMPK in the brain: Its roles in energy balance and neuroprotection","volume":"109","author":"Ronnett","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1152\/ajpendo.00578.2007","article-title":"Oxidative stress-induced insulin resistance in rat skeletal muscle: Role of glycogen synthase kinase-3","volume":"294","author":"Dokken","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1007\/s12035-018-1044-6","article-title":"Impact of Hypoglycemia on Brain Metabolism During Diabetes","volume":"55","author":"Rehni","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons","volume":"25","author":"Pacelli","year":"2015","journal-title":"Curr. Biol. CB"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.conb.2007.04.010","article-title":"Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson\u2019s disease","volume":"17","author":"Dodson","year":"2007","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.parkreldis.2021.06.002","article-title":"Prediabetes, type 2 diabetes mellitus and risk of Parkinson\u2019s disease: A population-based cohort study","volume":"89","author":"Compta","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc19-0760","article-title":"Association Between Glycemic Status and the Risk of Parkinson Disease: A Nationwide Population-Based Study","volume":"43","author":"Rhee","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_48","first-page":"e139","article-title":"Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study","volume":"91","author":"Goldacre","year":"2018","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson\u2019s disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/dc10-1922","article-title":"Diabetes and risk of Parkinson\u2019s disease","volume":"34","author":"Xu","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/mds.28551","article-title":"Type 2 Diabetes as a Determinant of Parkinson\u2019s Disease Risk and Progression","volume":"36","author":"Chohan","year":"2021","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/00207459309003322","article-title":"The relationship between diabetes mellitus and Parkinson\u2019s disease","volume":"69","author":"Sandyk","year":"1993","journal-title":"Int. J. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0304-3940(96)12357-0","article-title":"Insulin receptor mRNA in the substantia nigra in Parkinson\u2019s disease","volume":"204","author":"Takahashi","year":"1996","journal-title":"Neurosci. Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2967\/jnumed.116.183152","article-title":"Metabolic Imaging in Parkinson Disease","volume":"58","author":"Meles","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.2967\/jnumed.116.186403","article-title":"(18)F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment","volume":"58","author":"Meyer","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/mds.23213","article-title":"Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism","volume":"25","author":"Kono","year":"2010","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_58","first-page":"537","article-title":"Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson\u2019s Disease: A Cerebrospinal Fluid-Based Study","volume":"12","author":"Liguori","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41531-017-0014-4","article-title":"Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: Do PGK-1 mutations contribute to vulnerability to parkinsonism?","volume":"3","author":"Sakaue","year":"2017","journal-title":"NPJ Park. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.neurobiolaging.2013.11.001","article-title":"Dysregulation of glucose metabolism is an early event in sporadic Parkinson\u2019s disease","volume":"35","author":"Dunn","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.29333","article-title":"In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN-Related Parkinson\u2019s Disease","volume":"38","author":"Borsche","year":"2023","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1002\/ana.410320720","article-title":"Mitochondrial function in Parkinson\u2019s disease. The Royal Kings and Queens Parkinson\u2019s Disease Research Group","volume":"32","author":"Schapira","year":"1992","journal-title":"Ann. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","article-title":"Mitochondrial Dysfunction in Parkinson\u2019s Disease","volume":"24","author":"Moon","year":"2015","journal-title":"Exp. Neurobiol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Grotemeyer, A., McFleder, R.L., Wu, J., Wischhusen, J., and Ip, C.W. (2022). Neuroinflammation in Parkinson\u2019s Disease\u2014Putative Pathomechanisms and Targets for Disease-Modification. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.878771"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"13018","DOI":"10.1074\/jbc.271.22.13018","article-title":"Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase","volume":"271","author":"Peraldi","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10787-018-0458-0","article-title":"IL-6 signalling pathways and the development of type 2 diabetes","volume":"26","author":"Akbari","year":"2018","journal-title":"Inflammopharmacology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.neurobiolaging.2018.05.010","article-title":"Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: Preferential degeneration of the nigrostriatal motor pathway","volume":"69","author":"Renaud","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/mds.28124","article-title":"Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice","volume":"35","author":"Alberquilla","year":"2020","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_69","first-page":"371","article-title":"Unaltered lactate and glucose transporter levels in the MPTP mouse model of Parkinson\u2019s disease","volume":"3","author":"Puchades","year":"2013","journal-title":"J. Park. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neulet.2019.03.015","article-title":"Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson\u2019s disease mouse model: Endothelial and microglial effects","volume":"703","author":"Burks","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"114704","DOI":"10.1016\/j.expneurol.2024.114704","article-title":"Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson\u2019s disease","volume":"374","author":"Serra","year":"2024","journal-title":"Exp. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/jnr.22357","article-title":"Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson\u2019s disease","volume":"88","author":"Corona","year":"2010","journal-title":"J. Neurosci. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40035-022-00288-z","article-title":"Long-term hyperglycemia aggravates \u03b1-synuclein aggregation and dopaminergic neuronal loss in a Parkinson\u2019s disease mouse model","volume":"11","author":"Lv","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41419-023-06251-8","article-title":"Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization","volume":"14","author":"Lurette","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_75","first-page":"604","article-title":"alpha-Synuclein Overexpression in SH-SY5Y Human Neuroblastoma Cells Leads to the Accumulation of Thioflavin S-positive Aggregates and Impairment of Glycolysis","volume":"85","author":"Melnikova","year":"2020","journal-title":"Biochemistry"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cuvelier, E., Mequinion, M., Leghay, C., Sibran, W., Stievenard, A., Sarchione, A., Bonte, M.A., Vanbesien-Mailliot, C., Viltart, O., and Saitoski, K. (2018). Overexpression of Wild-Type Human Alpha-Synuclein Causes Metabolism Abnormalities in Thy1-aSYN Transgenic Mice. Front. Mol. Neurosci., 11.","DOI":"10.3389\/fnmol.2018.00321"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13098-019-0499-6","article-title":"Reducing effect of insulin resistance on alpha-synuclein gene expression in skeletal muscle","volume":"11","author":"Khoshi","year":"2019","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"16259","DOI":"10.1073\/pnas.1113884108","article-title":"Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Bogetofte, H., Jensen, P., Ryding, M., Schmidt, S.I., Okarmus, J., Ritter, L., Worm, C.S., Hohnholt, M.C., Azevedo, C., and Roybon, L. (2019). PARK2 Mutation Causes Metabolic Disturbances and Impaired Survival of Human iPSC-Derived Neurons. Front. Cell. Neurosci., 13.","DOI":"10.3389\/fncel.2019.00297"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12035-014-8927-y","article-title":"Early Expression of Parkinson\u2019s Disease-Related Mitochondrial Abnormalities in PINK1 Knockout Rats","volume":"53","author":"Villeneuve","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Deas, E., Piipari, K., Machhada, A., Li, A., Gutierrez-del-Arroyo, A., Withers, D.J., Wood, N.W., and Abramov, A.Y. (2014). PINK1 deficiency in beta-cells increases basal insulin secretion and improves glucose tolerance in mice. Open Biol., 4.","DOI":"10.1098\/rsob.140051"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1038\/ncomms5514","article-title":"PINK1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1","volume":"5","author":"Fernandez","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1074\/jbc.M114.606798","article-title":"Role of glucose metabolism and ATP in maintaining PINK1 levels during Parkin-mediated mitochondrial damage responses","volume":"290","author":"Lee","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1042\/BJ20141025","article-title":"DJ1 represses glycolysis and cell proliferation by transcriptionally up-regulating Pink1","volume":"467","author":"Fernandez","year":"2015","journal-title":"Biochem. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13024-017-0212-x","article-title":"Hexokinases link DJ-1 to the PINK1\/parkin pathway","volume":"12","author":"Hauser","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Funk, N., Munz, M., Ott, T., Brockmann, K., Wenninger-Weinzierl, A., Kuhn, R., Vogt-Weisenhorn, D., Giesert, F., Wurst, W., and Gasser, T. (2019). The Parkinson\u2019s disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-40808-y"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1248\/bpb.b20-00377","article-title":"LRRK2 Inhibition Ameliorates Dexamethasone-Induced Glucose Intolerance via Prevents Impairment in GLUT4 Membrane Translocation in Adipocytes","volume":"43","author":"Imai","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/2211-5463.13717","article-title":"LRRK2 negatively regulates glucose tolerance via regulation of membrane translocation of GLUT4 in adipocytes","volume":"13","author":"Kawakami","year":"2023","journal-title":"FEBS Open Bio"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Novak, P., Pimentel Maldonado, D.A., and Novak, V. (2019). Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214364"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: An old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"10856","DOI":"10.1038\/ncomms10856","article-title":"AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B","volume":"7","author":"Johanns","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/en.2006-1237","article-title":"Metformin inhibits adenosine 5\u2032-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons","volume":"148","author":"Gamba","year":"2007","journal-title":"Endocrinology"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Goel, S., Singh, R., Singh, V., Singh, H., Kumari, P., Chopra, H., Sharma, R., Nepovimova, E., Valis, M., and Kuca, K. (2022). Metformin: Activation of 5\u2032 AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.1022739"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","article-title":"Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide","volume":"62","author":"Suchy","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/15376516.2020.1741053","article-title":"Protective effect of metformin against rotenone-induced parkinsonism in mice","volume":"30","author":"Wang","year":"2020","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_97","first-page":"27207919","article-title":"Metformin Prevents Dopaminergic Neuron Death in MPTP\/P-Induced Mouse Model of Parkinson\u2019s Disease via Autophagy and Mitochondrial ROS Clearance","volume":"19","author":"Lu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol. Off. Sci. J. Coll. Int. Neuropsychopharmacol. (CINP)"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"26438","DOI":"10.1073\/pnas.2009838117","article-title":"Metformin rescues Parkinson\u2019s disease phenotypes caused by hyperactive mitochondria","volume":"117","author":"Mor","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.neuropharm.2017.08.015","article-title":"Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson\u2019s disease","volume":"125","author":"Katila","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Tayara, K., Espinosa-Oliva, A.M., Garc\u00eda-Dom\u00ednguez, I., Ismaiel, A.A., Boza-Serrano, A., Deierborg, T., Machado, A., Herrera, A.J., Venero, J.L., and de Pablos, R.M. (2018). Divergent Effects of Metformin on an Inflammatory Model of Parkinson\u2019s Disease. Front. Cell. Neurosci., 12.","DOI":"10.3389\/fncel.2018.00440"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clnesp.2024.02.018","article-title":"Metformin use is associated with reduced mortality risk in diabetic patients with Parkinson\u2019s disease","volume":"60","author":"Pezzoli","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson\u2019s disease occurring with Type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"Wahlqvist","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.taap.2016.03.004","article-title":"Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system","volume":"298","author":"Ismaiel","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/BF00401417","article-title":"The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work?","volume":"35","author":"Henquin","year":"1992","journal-title":"Diabetologia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tem.2005.01.008","article-title":"The role of insulin receptor signaling in the brain","volume":"16","author":"Plum","year":"2005","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/db14-0568","article-title":"Insulin action in brain regulates systemic metabolism and brain function","volume":"63","author":"Kleinridders","year":"2014","journal-title":"Diabetes"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1074\/jbc.M111.313080","article-title":"Insulin promotes neuronal survival via the alternatively spliced protein kinase C\u03b4II isoform","volume":"287","author":"Apostolatos","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/fcp.12434","article-title":"Glimepiride prevents paraquat-induced Parkinsonism in mice: Involvement of oxidative stress and neuroinflammation","volume":"33","author":"Ishola","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12640-023-00637-4","article-title":"Glimepiride Prevents 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Dopamine Neurons Degeneration Through Attenuation of Glia Activation and Oxidative Stress in Mice","volume":"41","author":"Ishola","year":"2023","journal-title":"Neurotox. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"118070","DOI":"10.1016\/j.lfs.2020.118070","article-title":"The role of K(ATP) channel blockade and activation in the protection against neurodegeneration in the rotenone model of Parkinson\u2019s disease","volume":"257","author":"Abdelkader","year":"2020","journal-title":"Life Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e13618","DOI":"10.1111\/acel.13618","article-title":"Role of upregulation of the K(ATP) channel subunit SUR1 in dopaminergic neuron degeneration in Parkinson\u2019s disease","volume":"21","author":"Liu","year":"2022","journal-title":"Aging Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mds.29341","article-title":"Genetic Variants in Sulfonylurea Targets Affect Parkinson\u2019s Disease Risk: A Two-Sample Mendelian Randomization Study","volume":"38","author":"Aziz","year":"2023","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/nn.3185","article-title":"K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration","volume":"15","author":"Schiemann","year":"2012","journal-title":"Nat. Neurosci."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kim, E.Y., Im, J.H., Han, J., and Cho, W.J. (2024). Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer\u2019s disease. Bioorg Med. Chem. Lett., 99.","DOI":"10.1016\/j.bmcl.2024.129622"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-2007-11108","article-title":"Rosiglitazone induces mitochondrial biogenesis in mouse brain","volume":"11","author":"Strum","year":"2007","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00280-013-2084-2","article-title":"The PPAR\u03b3 agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model","volume":"71","author":"Grommes","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4089214","DOI":"10.1155\/2017\/4089214","article-title":"Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic Neurons In Vivo and In Vitro in Parkinson\u2019s Disease","volume":"2017","author":"Wang","year":"2017","journal-title":"PPAR Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","article-title":"Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson\u2019s disease","volume":"82","author":"Breidert","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.bbr.2014.08.014","article-title":"Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine","volume":"274","author":"Barbiero","year":"2014","journal-title":"Behav. Brain Res."},{"key":"ref_125","first-page":"514","article-title":"Differential susceptibility to the PPAR-\u03b3 agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson\u2019s disease","volume":"65","author":"Laloux","year":"2012","journal-title":"Pharmacol. Res. Off. J. Ital. Pharmacol. Soc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/mds.27128","article-title":"Glitazone use associated with reduced risk of Parkinson\u2019s disease","volume":"32","author":"Brakedal","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jocn.2022.10.023","article-title":"Pioglitazone use is associated with reduced risk of Parkinson\u2019s disease in patients with diabetes: A systematic review and meta-analysis","volume":"106","author":"Chen","year":"2022","journal-title":"J. Clin. Neurosci."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators (2015). Pioglitazone in early Parkinson\u2019s disease: A phase 2, multicentre, double-blind, randomised trial. Lancet Neurol., 14, 795\u2013803.","DOI":"10.1016\/S1474-4422(15)00144-1"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e023302","DOI":"10.1136\/bmjopen-2018-023302","article-title":"Pioglitazone use and Parkinson\u2019s disease: A retrospective cohort study in Taiwan","volume":"8","author":"Wu","year":"2018","journal-title":"BMJ Open"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","volume":"9","author":"Hermansen","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.beem.2007.07.005","article-title":"DPP-4 inhibitors","volume":"21","year":"2007","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Pariyar, R., Bastola, T., Lee, D.H., and Seo, J. (2022). Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042388"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1007\/s11357-024-01116-0","article-title":"DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson\u2019s disease","volume":"46","author":"Yu","year":"2024","journal-title":"Geroscience"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: A cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain A J. Neurol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.diabet.2016.09.005","article-title":"Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials","volume":"43","author":"Rehman","year":"2017","journal-title":"Diabetes Metab."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jcem.86.8.7743","article-title":"Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes","volume":"86","author":"Madsbad","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_144","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Hunter, K., and H\u00f6lscher, C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci., 13.","DOI":"10.1186\/1471-2202-13-33"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: Mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Alharbi, S.H. (2024). Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther. Adv. Endocrinol. Metab., 15.","DOI":"10.1177\/20420188231222367"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Krasner, N.M., Ido, Y., Ruderman, N.B., and Cacicedo, J.M. (2014). Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097554"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2015.09.035","article-title":"A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson\u2019s disease by increasing expression of BNDF","volume":"1634","author":"Ji","year":"2016","journal-title":"Brain Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuropharm.2017.09.023","article-title":"Protective effects of the GLP-1 mimetic exendin-4 in Parkinson\u2019s disease","volume":"136 Pt B","author":"Athauda","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Dickson","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Norton","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","article-title":"Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects","volume":"2","author":"Seman","year":"2013","journal-title":"Clin. Pharmacol. Drug. Dev."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Pawlos, A., Broncel, M., Wo\u017aniak, E., and Gorzelak-Pabi\u015b, P. (2021). Neuroprotective Effect of SGLT2 Inhibitors. Molecules, 26.","DOI":"10.3390\/molecules26237213"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Scisciola, L., Cataldo, V., Taktaz, F., Fontanella, R.A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., De Angelis, A., and Sportiello, L. (2022). Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1008922"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/fcp.12548","article-title":"Empagliflozin attenuates transient cerebral ischemia\/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway","volume":"34","author":"Amin","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jsps.2022.03.005","article-title":"Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of \u03b1-synuclein and Parkin levels in rotenone-induced Parkinson\u2019s disease in rats","volume":"30","author":"Ahmed","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10787-023-01384-w","article-title":"Empagliflozin repurposing in Parkinson\u2019s disease; modulation of oxidative stress, neuroinflammation, AMPK\/SIRT-1\/PGC-1\u03b1, and wnt\/\u03b2-catenin pathways","volume":"32","author":"Mohammed","year":"2024","journal-title":"Inflammopharmacology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","article-title":"Targeting ROS-Dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson\u2019s Disease Rat Model","volume":"12","author":"Arab","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Lin, K.J., Wang, T.J., Chen, S.D., Lin, K.L., Liou, C.W., Lan, M.Y., Chuang, Y.C., Chuang, J.H., Wang, P.W., and Lee, J.J. (2021). Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants, 10.","DOI":"10.3390\/antiox10121935"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1507\/endocrj.EJ13-0019","article-title":"Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus","volume":"60","author":"Okada","year":"2013","journal-title":"Endocr. J."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0026-0495(85)90010-1","article-title":"alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus","volume":"34","author":"Dimitriadis","year":"1985","journal-title":"Metabolism"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Wang, H. (2021). MicroRNAs, Parkinson\u2019s Disease, and Diabetes Mellitus. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062953"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.nut.2008.11.015","article-title":"The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes","volume":"25","author":"Fukaya","year":"2009","journal-title":"Nutrition"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"22650","DOI":"10.1039\/D2RA04228B","article-title":"Alpha glucosidase inhibitory properties of a few bioactive compounds isolated from black rice bran: Combined in vitro and in silico evidence supporting the antidiabetic effect of black rice","volume":"12","author":"Bhuyan","year":"2022","journal-title":"RSC Adv."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Han, J.H., Lee, E.J., Park, W., Ha, K.T., and Chung, H.S. (2023). Natural compounds as lactate dehydrogenase inhibitors: Potential therapeutics for lactate dehydrogenase inhibitors-related diseases. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1275000"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-018-0260-x","article-title":"Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration","volume":"13","author":"Quansah","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Teil, M., Arotcarena, M.L., and Dehay, B. (2021). A New Rise of Non-Human Primate Models of Synucleinopathies. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030272"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Ma, S.X., and Lim, S.B. (2021). Single-Cell RNA Sequencing in Parkinson\u2019s Disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040368"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/22\/1876\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:31:31Z","timestamp":1760113891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/22\/1876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":183,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cells13221876"],"URL":"https:\/\/doi.org\/10.3390\/cells13221876","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}